MERTK
ENSG00000153208
Target class
Kinase
Chromosome
2
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- MERTK
- Gene name
- MER proto-oncogene, tyrosine kinase
- Gene symbol
- MERTK
- Protein name
- Tyrosine-protein kinase Mer (EC 2.7.10.1) (Proto-oncogene c-Mer) (Receptor tyrosine kinase MerTK)
- mer
- RP38
- c-Eyk
- Tyro12
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|Fibronectin type III domain containing|I-set domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 52.43
- Tissue specificity (Gini)
- 0.408
- Tissue specificity (tau)
- 0.729
- KEGG gene identifiers
- hsa:10461
- Protein interaction confidence
- 0.803056
- Protein interaction partners
- 18
- R-HSA-202733
- R-HSA-9918485
- End position
- 112029561
- Start position
- 111898607
- Chromosome
- 2
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein .
- Acrosome
- Mid piece
- Plasma membrane
- Principal piece
Publication evidence
- PubMed 32640697
- Tissue specificity (tau)
- 0.728968
- Expression inequality (Gini)
- 0.407869
Expression in transcripts per million
- Adrenal Gland
- 52.43
- Artery - Tibial
- 46.64
- Spleen
- 37.93
- Artery - Aorta
- 33.87
- Testis
- 31.71
Expression in transcripts per million
- Adrenal Gland52.43
- Artery - Tibial46.64
- Spleen37.93
- Artery - Aorta33.87
- Testis31.71
- Fallopian Tube29.23
- Artery - Coronary28.97
- Adipose - Subcutaneous24.93
- Cervix - Endocervix24.78
- Nerve - Tibial23.98
- Bladder22.11
- Lung21.69
- Esophagus - Gastroesophageal Junction21.38
- Cervix - Ectocervix20.99
- Ovary20.64
- Uterus19.67
- Breast - Mammary Tissue18.89
- Pituitary18.66
- Adipose - Visceral (Omentum)17.92
- Thyroid17.62
- Prostate17.57
- Small Intestine - Terminal Ileum17.33
- Vagina14.76
- Esophagus - Muscularis14.57
- Stomach14.08
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0006909
- GO:0007166
- GO:0007267
- GO:0050766
- GO:2000107
- GO:0005576
- GO:0005737
- GO:0005886
- GO:0010008
- GO:0004714
- GO:0005515
Related records
Trials (175)
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
- A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
- A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
- A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma
- A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
- A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)
- A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
- A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
- A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
- A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
- A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
- A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Drugs (11)
- Adrixetinib
- BMS-777607
- BMS-794833
- Denfivontinib
- Gilteritinib
- Merestinib
- MK-2461
- Ningetinib Proto-oncogene tyrosine-protein kinase MER inhibitor
- Sitravatinib
- SLC-391
- Zanzalintinib